BUY ETHYLONE CRYSTAL ONLINE
Buy Ethylone Crystal Online,
It is possible to produce ethylone crystal in a laboratory by following the following procedure: The product obtained by dissolving 3,4-methylenedioxybutyrophenone in dichloromethane and converting it to bromine is known as 3′,4′-methylenedioxy-2-bromobutyrophenone. After that, the product was dissolved in dichloromethane, and it was added to an aqueous solution that included forty percent methylamine. After that, HCl was added. After removing the aqueous layer, sodium bicarbonate was used to turn it into an alkaline solution. An amine ether was used in the process of extracting the amine. One drop of ether and one drop of HCl solution were added in order to obtain butylone.
Butylone Crystal, in a manner comparable to that of MDMA and Methylone, is responsible for a rise in the levels of extracellular monoamines.
In their work from 1967, Koeppe, Ludwig, and Zeile are credited with being the first people to successfully synthesize butylone crystal. It remained a little-known academic byproduct until 2005, when it first appeared on the market as a so-called designer medication. [1] Butylone and MBDB are related to one another in the same way as methylone is related to MDMA (also known as “Ecstasy”). The first year that this chemical was the subject of serious scientific investigation was 2009, when it was discovered that its metabolism was comparable to that of other medications in the same class, such as methylone.
Butylone, also known as -keto-N-methylbenzodioxolylbutanamine (k-MBDB), is a psychoactive substance that belongs to the phenethylamine chemical family. It has been described as having entactogen, psychedelic, and stimulant properties. It is the substituted methylenedioxyphenethylamine analogue of buphedrone as well as the -keto analogue of MBDB (which stands for substituted cathinone).
As can be seen in the image, bk-MBDB may be broken down into three primary metabolic processes.
The breakdown of bk-MBDB into the metabolites 4-OH-3-MeO and 3-OH-4-MeO in human urine occurs as a consequence of demethylenation, which is then followed by O-methylation. The second route involves the reduction of beta-ketones to produce beta-ketone reduced metabolites. A N-dealkylation into N-dealkyl metabolites is the third step that may be taken. The first two paths are seen more often than the third option. The 4-OH-3-MeO metabolite is the one that is found the most often.
Reviews
There are no reviews yet.